A human epidermal growth factor receptor 2 expression-based approach to neoadjuvant chemotherapy for operable breast cancer.
Ishikawa
Takashi
T
Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan. tishik@urahp.yokohama-cu.ac.jp
Shimizu
Daisuke
D
Sasaki
Takeshi
T
Morita
Satoshi
S
Tanabe
Mikiko
M
Ota
Ikuko
I
Kawachi
Kae
K
Nozawa
Akinori
A
Chishima
Takashi
T
Ichikawa
Yasushi
Y
Endo
Itaru
I
Shimada
Hiroshi
H
D000293:Adolescent; D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003520:Cyclophosphamide / Q000627:therapeutic use; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D043823:Taxoids / Q000627:therapeutic use; D055815:Young Adult
D018943:Anthracyclines; D000970:Antineoplastic Agents; D003520:Cyclophosphamide; D000077143:Docetaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids